ABBV-951

ABBV-951 is subcutaneous delivery of Levodopa/Carbidopa being investigated for the treatment of Parkinson’s disease.

Type of Molecule

Small Molecule

Target

Dopamine Receptor

Product Type

New Indication

Potential Indication	Region	Phase (1, 2, 3, Submitted, Approved)
Parkinson's Disease	n/a	Phase 1

This site uses cookies to personalize content, save your preferences and track the site’s performance. Learn more, including how to disable certain cookies on our Privacy Page. Click OK to continue.